Methylenetetrahydrofolate reductase (MTHFR) C677T genetic polymorphism and late infarct-related coronary artery patency after thrombolysis

J Thromb Thrombolysis. 2009 May;27(4):413-20. doi: 10.1007/s11239-008-0235-9. Epub 2008 Jun 25.

Abstract

In patients with acute myocardial infarction (AMI), a persistently occluded infarct-related artery (IRA) is associated with unfavorable prognosis and genetic factors may be contributing factors to thrombolysis failure. One-hundred and one consecutive patients treated with intravenous thrombolysis during AMI were blind-tested for methylenetetrahydrofolate reductase (MTHFR) and circulating homocysteine levels and underwent protocol angiography 14 +/- 6 days after the event. IRA was patent in 61 patients and occluded in 40. Overall MTHFR 677TT frequency was 22%. Patients with MTHFR 677TT homozygosis had higher prevalence of occluded IRA (73%) versus those with MTHFR 677CT/CC genotype (30%, P < 0.001); MTHFR 677TT genotype predicted independently the risk of IRA occlusion with a specificity of 90% (odds ratio 3.8, 95% confidence interval 1.1-9.1; P = 0.03). Moreover, patients with occluded IRA and MTHFR 677TT genotype had the highest homocysteine levels (21 +/- 7.6 micromol/l vs. < or =14.9 +/- 3.8 micromol/l; P = 0.011). In patients with AMI, MTHFR 677TT homozygosis is independently associated with a persistently occluded IRA after thrombolysis. This finding may have pathophysiological and therapeutic implications for recanalization strategies in patients with AMI.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Coronary Vessels / enzymology*
  • Coronary Vessels / physiopathology
  • Female
  • Genotype
  • Humans
  • Male
  • Methylenetetrahydrofolate Reductase (NADPH2) / genetics*
  • Middle Aged
  • Myocardial Infarction / enzymology
  • Myocardial Infarction / genetics*
  • Myocardial Infarction / physiopathology
  • Polymorphism, Genetic / genetics*
  • Prospective Studies
  • Thrombolytic Therapy* / adverse effects
  • Vascular Patency / genetics*

Substances

  • Methylenetetrahydrofolate Reductase (NADPH2)